Skin Cancer & Melanoma

The agency has set a PDUFA date of April 10, 2026, for the decision on RP1 plus nivolumab in patients with previously treated advanced melanoma.

A novel cancer vaccine, IO102-IO103, combined with pembrolizumab, showed promising results in improving PFS for advanced melanoma.

Cemiplimab showed comparable rates of second primary tumors and improved disease-free survival in high-risk cutaneous squamous cell carcinoma patients.

Nine-year final results from the CheckMate 238 trial demonstrated that adjuvant nivolumab significantly improved time to second disease progression.

BNT111 combined with cemiplimab showed promising efficacy in treating PD-(L) PD-L1-relapsed/refractory melanoma, achieving an 18.1% objective response rate.

Single-agent pembrolizumab achieved an ORR of 89%, with a 37% CR rate, in patients with advanced desmoplastic melanoma in the phase 2 SWOG S1512 trial.

Data from a phase 1/1b trial showed that WTX-124 achieved clinically meaningful activity in those with advanced melanoma following SOC immunotherapy.

Findings from the phase 3 C-POST trial support the FDA approval of cemiplimab in this cutaneous squamous cell carcinoma population.

Pathologists should try to educate oncologists about the sensitivity and specificity of assays to help optimize care plans, said David Rimm, MD, PhD.

Adjuvanted imsapepimut and etimupepimut plus pembrolizumab did not yield a statistically significant PFS improvement as treatment for advanced melanoma.

Artificial intelligence used in conjunction with clinicians may help standardize and expedite pathology workflows and reduce variability in TIL scoring.

An 80% disease metastasis–free survival rate occurred in those with uveal melanoma who received a brachytherapy plaque with vitrectomy and silicone oil.

Clinicians discuss the best treatment options for a 46-year-old woman diagnosed with BRAF+ melanoma.

Two studies were recently published that validated the use of the DecisionDx-SCC test as a tool for the treatment of cutaneous squamous cell carcinoma.

D-MNA achieved complete clinical clearance in 60% of patients, with no dose-limiting toxicities or serious adverse effects observed in those with basal cell carcinoma of the skin.

The novel cancer vaccine plus pembrolizumab missed statistical significance but generated a clinically meaningful improvement in advanced melanoma.

At 4 years, about 20% of patients with advanced melanoma who received tumor-infiltrating lymphocyte therapy were alive and responding to treatment.

Innovative oncolytic virus therapies transform advanced melanoma treatment, enhance patient outcomes, and overcome resistance to traditional immunotherapies.

Bhuvanesh Singh, MD, has big plans for enhancing the skin cancer program at Northwell Health.

Experts analyze the evolving landscape of melanoma treatment, highlighting key clinical trials and strategies for optimizing patient outcomes.

The SCIB1/iSCIB1+ cancer vaccines plus nivolumab and ipilimumab improved responses vs nivolumab and ipilimumab alone in patients with melanoma.

The FDA indicated that data from the phase 1/2 IGNYTE trial were not adequate to provide evidence of effectiveness.

The B7-H3–low and TIGIT-high biosignatures correlated with superior event-free survival outcomes in those with melanoma treated with the combination.

ATR04-484 showed inhibition of both methicillin-sensitive and methicillin-resistant Staphylococcus aureus bacteria strains, which are associated with rash.

Phase 3 data demonstrate the potential utility of BRAF/MEK inhibition in the adjuvant setting for patients with stage IIB/IIC BRAF V600–mutant melanoma.

A phase 3 trial evaluating frontline IFx-2.0 with pembrolizumab in advanced/metastatic Merkel cell carcinoma is planned to start later in June 2025.

Data from the IGNYTE trial demonstrate the development of a robust systemic antitumor response following treatment with RP1.

Compared with nivolumab alone, nivolumab/relatlimab did not improve RFS in patients with resected stage III to IV melanoma.

The combination elicited a clinical benefit rate of 63.0% and an overall response rate of 22.2% in anti–PD-L1–refractory melanoma with melanoma brain metastases.

Efficacy across most patient subgroups appeared to be consistent with relatlimab/nivolumab vs ipilimumab/nivolumab in patients with advanced melanoma.